ROCHE Pharmaceuticals Xeloda
(capecitabine) is now available on
the Pharmaceutical Benefits Scheme
in combination with oxaliplatin for
the treatment of metastatic colorectal
cancer, and in combination with a
cisplastin-based regimen for the
treatment of advanced
oesophagogastric cancer.
Xeloda is an oral alternative to the
intravenous chemotherapy fluorouracil.The above article was sent to subscribers in Pharmacy Daily's issue from 30 Aug 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Aug 10
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.